/TWST

TWST Stock - Twist Bioscience Corporation

Q: What is the analyst price target for TWST?

Analyst price target information is not currently available for TWST.

Q: What is TWST's market cap?

Market capitalization information is not currently available for TWST.

Healthcare|Medical - Diagnostics & Research|NASDAQ

$40.22+5.73%

+$2.18 (+5.73%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+1.1%upside

Target: $40.66

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for TWST

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.19

52W High$55.33

52W Low$23.30

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$376.57M	$312.97M	$245.11M	$203.56M	$132.33M
Gross Profit	$191.00M	$133.35M	$89.73M	$84.23M	$51.71M
Gross Margin	50.7%	42.6%	36.6%	41.4%	39.1%
Operating Income	$-136,259,000	$-220,831,000	$-217,159,000	$-234,776,000	$-152,726,000
Net Income	$-77,670,000	$-208,726,000	$-204,618,000	$-217,863,000	$-152,098,000
Net Margin	-20.6%	-66.7%	-83.5%	-107.0%	-114.9%
EPS	$-1.30	$-3.60	$-3.60	$-4.04	$-3.15

Company Overview

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Visit Website

Earnings History & Surprises

TWST

Beat Rate

78%

Last 18 quarters

Avg Surprise

+8.4%

EPS vs Estimate

Beats / Misses

14/4

Last 12 quarters

Latest EPS

$-0.45

Q4 2025

EPS Surprise History

Q1 24

+6.3%

$-0.75vs$-0.80

Q2 24

+6.0%

$-0.79vs$-0.84

Q3 24

-8.9%

$-0.86vs$-0.79

Q4 24

+17.4%

$-0.59vs$-0.71

Q1 25

+14.5%

$-0.53vs$-0.62

Q2 25

-17.9%

$-0.66vs$-0.56

Q3 25

+13.0%

$-0.47vs$-0.54

Q4 25

+10.0%

$-0.45vs$-0.50

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 4, 2026	—	—	—	—
Q1 2026	Feb 2, 2026	$-0.49	—	—	—
Q4 2025	Nov 14, 2025	$-0.50	$-0.45	+10.0%	✓ BEAT
Q3 2025	Aug 4, 2025	$-0.54	$-0.47	+13.0%	✓ BEAT
Q2 2025	May 5, 2025	$-0.56	$-0.66	-17.9%	✗ MISS
Q1 2025	Feb 3, 2025	$-0.62	$-0.53	+14.5%	✓ BEAT
Q4 2024	Nov 18, 2024	$-0.71	$-0.59	+17.4%	✓ BEAT
Q3 2024	Aug 2, 2024	$-0.79	$-0.86	-8.9%	✗ MISS
Q2 2024	May 2, 2024	$-0.84	$-0.79	+6.0%	✓ BEAT
Q1 2024	Feb 2, 2024	$-0.80	$-0.75	+6.3%	✓ BEAT
Q4 2023	Nov 17, 2023	$-0.94	$-0.81	+13.8%	✓ BEAT
Q3 2023	Aug 4, 2023	$-1.14	$-1.01	+11.4%	✓ BEAT
Q2 2023	May 5, 2023	$-1.09	$-1.06	+2.8%	✓ BEAT
Q1 2023	Feb 3, 2023	$-1.09	$-0.74	+32.1%	✓ BEAT
Q4 2022	Nov 18, 2022	$-1.28	$-0.91	+28.9%	✓ BEAT
Q3 2022	Aug 5, 2022	$-1.30	$-1.08	+16.9%	✓ BEAT
Q2 2022	May 5, 2022	$-1.26	$-1.24	+1.6%	✓ BEAT
Q1 2022	Feb 4, 2022	$-1.08	$-0.91	+15.7%	✓ BEAT
Q4 2021	Nov 22, 2021	$-0.80	$-0.84	-5.0%	✗ MISS
Q3 2021	Aug 6, 2021	$-0.76	$-0.82	-7.9%	✗ MISS

Frequently Asked Questions about TWST

What is TWST's current stock price?

Twist Bioscience Corporation (TWST) is currently trading at $40.22 per share. The stock has moved +5.73% today.

What is the analyst price target for TWST?

The average analyst price target for TWST is $40.67, based on 1 analyst.

What sector is Twist Bioscience Corporation in?

Twist Bioscience Corporation operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.

What is TWST's market cap?

Twist Bioscience Corporation has a market capitalization of $2.41 billion, making it a mid-cap company.

Does TWST pay dividends?

No, Twist Bioscience Corporation does not currently pay a dividend to shareholders.